RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Enrollment Closed
1

The PODO Trial

Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis

Breve descripción

The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio).

Médico del ensayo / Coordinador del estudio

Andrey Cybulsky

Correo electrónico Teléfono
Nombre del sitio

Centre for Innovative Medicine, Research Institute of the McGill University Health Centre
1001 Decarie Blvd., Room EM1.3238, Montreal, QC H4A 3J1

Patrocinador

Pfizer Inc.

Fármaco del estudio

PF-06730512

Matrícula estimada

44

Fecha de finalización estimada

May, 2023

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Encuentre otras ubicaciones para esta prueba:
Inscripciones cerradas
1

The PODO Trial

Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis

Breve descripción

The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio).

La prueba es para personas con

Primary focal segmental glomerulosclerosis (FSGS)

Objetivo del estudio

To evaluate the safety, tolerability, and possibily efficacy of PF-06730512 in patients with FSGS.

¿Qué implica para el paciente?

Patients will participate for 13 weeks, receiving an intravenous infusion of the study drug weekly.

Sobre el medicamento o la intervención

PF-06730512 works as an antagonist, meaning it possibly reduces the biologic activity that is associated with FSGS.

Encuentre otras ubicaciones para esta prueba:
Montreal, QC, Canada (McGill)
Preguntas frecuentes

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

Ver otras preguntas frecuentes